Zhejiang Huahai Pharmaceutical (600521) Stock Overview
Operates as a pharmaceutical company in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
600521 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Zhejiang Huahai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.56 |
| 52 Week High | CN¥23.83 |
| 52 Week Low | CN¥13.49 |
| Beta | 0.41 |
| 1 Month Change | -1.39% |
| 3 Month Change | 46.02% |
| 1 Year Change | 15.57% |
| 3 Year Change | -3.02% |
| 5 Year Change | -43.89% |
| Change since IPO | 775.72% |
Recent News & Updates
Recent updates
Cautious Investors Not Rewarding Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Performance Completely
Feb 20
Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Somewhat Strained Balance Sheet
Jan 27Investors Holding Back On Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)
Oct 22Here's Why Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Meaningful Debt Burden
Sep 25Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 20Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt
May 28There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings
May 06Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel
Mar 22Shareholder Returns
| 600521 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -10.6% | 1.0% | 1.2% |
| 1Y | 15.6% | 25.3% | 23.9% |
Return vs Industry: 600521 underperformed the CN Pharmaceuticals industry which returned 25.3% over the past year.
Return vs Market: 600521 underperformed the CN Market which returned 23.9% over the past year.
Price Volatility
| 600521 volatility | |
|---|---|
| 600521 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in CN Market | 8.6% |
| 10% least volatile stocks in CN Market | 2.9% |
Stable Share Price: 600521's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 600521's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 9,065 | Bao Hua Chen | www.huahaipharm.com |
Zhejiang Huahai Pharmaceutical Co., Ltd. operates as a pharmaceutical company in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as high-density polyethylene bottles and polypropylene caps for pharmaceuticals.
Zhejiang Huahai Pharmaceutical Co., Ltd. Fundamentals Summary
| 600521 fundamental statistics | |
|---|---|
| Market cap | CN¥30.95b |
| Earnings (TTM) | CN¥1.15b |
| Revenue (TTM) | CN¥9.42b |
Is 600521 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600521 income statement (TTM) | |
|---|---|
| Revenue | CN¥9.42b |
| Cost of Revenue | CN¥3.57b |
| Gross Profit | CN¥5.85b |
| Other Expenses | CN¥4.71b |
| Earnings | CN¥1.15b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 30, 2025
| Earnings per share (EPS) | 0.77 |
| Gross Margin | 62.13% |
| Net Profit Margin | 12.16% |
| Debt/Equity Ratio | 77.7% |
How did 600521 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/11 16:26 |
| End of Day Share Price | 2025/07/11 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zhejiang Huahai Pharmaceutical Co., Ltd. is covered by 21 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wanhua Wu | China International Capital Corporation Limited |
| Shanshan Li | China Merchants Securities Co. Ltd. |
| Ling Bo Tu | China Minzu Securities |